<?xml version="1.0" encoding="UTF-8" standalone="yes"?><?xml-stylesheet type="text/xsl" href="/oai-pmh-repository/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2026-10-14T10:34:50Z</responseDate>
    <request verb="GetRecord" identifier="oai:data.mendeley.com/5xtc2z3vs2.1" metadataPrefix="oai_dc">https://data.mendeley.com/oai</request>
    <GetRecord>
        <record>
            <header>
                <identifier>oai:data.mendeley.com/5xtc2z3vs2.1</identifier>
                <datestamp>2026-07-08T17:25:09Z</datestamp>
            </header>
            <metadata><oai_dc:dc xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <dc:creator>Wan, Li</dc:creator>
    <dc:title>Non-invasive prediction of Dupilumab response in facial Atopic Dermatitis lesions based on  early post-treatment Reflectance  Confocal Microscopy features</dc:title>
    <dc:publisher>Mendeley Data</dc:publisher>
    <dc:description>Background: Non-invasive prediction of the efficacy of dupilumab on facial lesions in patients with atopic dermatitis (AD) remains poorly defined.
Objectives: This study aimed to explore reflectance confocal microscopy (RCM),  a  non-invasive  method,  for  predicting  dupilumab  efficacy  in treating  facial AD lesions  and to realize  effective prediction via  deep learning.
Methods:  Data  from  a  prospective  study  included  49  AD  patients received dupilumab treatment conducted between May 2023 and June 2025  were  collected  and  analyzed.  Patients  were  categorized  into &apos;responder&apos; and &apos;nonresponder&apos; groups based on whether achieved EASI75 at  16  week.  RCM  was utilized to  evaluate  facial  lesions prior to  and following treatment to identify intergroup differences. Deep learning was employed to construct a prediction model.
Results: Dermal papillary dilation (AUC=0.83,  P&lt;0.001) and tortuous papillary capillary dilation ((AUC=0.81,     P&lt;0.001) at 4 weeks post-treatment correlated significantly with therapeutic non-response. The ResNet101-based deep learning model, trained on RCM images from the 4-week interval, demonstrated robust predictive performance across 5-fold cross-validation, achieving a mean accuracy of 0.7280 ± 0.0215 and a final test AUC of 0.796. The model specifically identified non-responders with a precision of 0.8120 ± 0.0153 and an F1-score of 0.7400 ± 0.0239. Saliency heatmaps further visualized the model&apos;s decision-making basis, aligning with key pathological RCM features.
Limitations: The present study is characterized by a relatively modest sample size, which is consistent with the exploratory nature of this investigation.
Conclusions: Early post-treatment RCM features can effectively predict the  efficacy  of  dupilumab  in  facial  AD  lesions  combined  with  deep learning.

Supplementary Data Figures for Publication</dc:description>
    <dc:subject>Image Classification</dc:subject>
    <dc:type>Dataset</dc:type>
    <dc:identifier>doi:10.17632/5xtc2z3vs2.1</dc:identifier>
    <dc:identifier>oai:data.mendeley.com/5xtc2z3vs2.1</dc:identifier>
    <dc:rights>Creative Commons Attribution 4.0 International</dc:rights>
    <dc:rights>http://creativecommons.org/licenses/by/4.0</dc:rights>
    <dc:relation>https://data.mendeley.com/datasets/5xtc2z3vs2</dc:relation>
    <dc:date>2026-07-08T17:25:09Z</dc:date>
</oai_dc:dc></metadata>
        </record>
    </GetRecord>
</OAI-PMH>
